Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Collegium Pharmaceutical
COLL
5
Enerpac Tool
EPAC
US Stock MarketDetailed Quotes
MYGN Myriad Genetics
- 7.700
- +0.140+1.85%
Close May 5 16:00 ET
- 8.000
- +0.300+3.90%
Post 17:43 ET
709.72MMarket Cap-5.46P/E (TTM)
7.780High7.360Low1.54MVolume7.550Open7.560Pre Close11.84MTurnover1.72%Turnover RatioLossP/E (Static)92.17MShares29.30052wk High1.01P/B692.04MFloat Cap6.94052wk Low--Dividend TTM89.87MShs Float69.000Historical High--Div YieldTTM5.56%Amplitude1.438Historical Low7.666Avg Price1Lot Size
About Myriad Genetics Company
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.
Company Profile
SymbolMYGN
Company NameMyriad Genetics
Listing DateOct 6, 1995
Issue Price18.00
Founded1991
CEOMr. Samraat S. Raha
MarketNASDAQ
Employees2700
Fiscal Year Ends12-31
Address322 North 2200 West
CitySalt Lake City
ProvinceUtah
CountryUnited States of America
Zip Code84116
Phone1-801-584-3600
Websitehttp://www.myriad.com
Company Executives
- Name
- Position
- Salary
- Samraat S. Raha
- President, Chief Executive Officer and Director
- 4.39M
- Mark S. Verratti
- Chief Operating Officer
- 3.71M
- Natalie Munk
- Chief Accounting Officer
- --
- Shereen Solaiman
- Chief People Officer
- --
- Jennifer Fox
- Chief Legal Officer
- --
- Scott J. Leffler
- Chief Financial Officer
- 6.15M
- Kevin Richard Haas
- Chief Technology Officer
- --
- Dale Muzzey
- Chief Scientific Officer
- 3.01M
- Margaret Ancona
- Senior Vice President and Chief of Staff
- --
- S. Louise Phanstiel
- Chairman of the Board
- 563.50K
- Rashmi Kumar
- Independent Director
- 433.50K
- Colleen F. Reitan
- Independent Director
- 443.50K
- Paul M. Bisaro
- Independent Director
- 449.35K
- Mark S. Davis
- Independent Director
- 350.00K
- Dr. Lee N. Newcomer, M.D.
- Independent Director
- 448.00K
- Dr. Heiner Dreismann,PhD
- Independent Director
- 443.50K
- Dr. Daniel M. Skovronsky, M.D.,PhD
- Independent Director
- 433.50K
Market Insights
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call